FindTrial
Sign In

To Study the role of vitamin D in asthma

EFFECT OF VITAMIN D ON ASTHMA CONTROL AND QUALITY OF LIFE IN PATIENTS OF MODERATE BRONCHIAL ASTHMA WITH VITAMIN D DEFICIENCY: A PROSPECTIVE STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/11/047299
Enrollment
60
Registered
2022-11-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Vitamin D: Vitamin D 60,000 IU per week in sachet form for Vitamin D deficient patients (in asthmatics) for 3 months Control Intervention1: NIL: NIL

Sponsors

Maulana azad medical college and associated Lok Nayak Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with moderate asthma diagnosed according to latest GINA guidelines [2022] for at least 1 month

Exclusion criteria

Exclusion criteria: 1.History of any chronic disease other than asthma (like cancer, liver disease, gall bladder disease, diabetes, uncontrolled hypertension and GI disorders affecting vitamin D absorption). 2.Respiratory tract infection within past 4 weeks. 3.Known allergy to vitamin D or taking vitamin D supplements. 4.Hypercalcemia ( >11mg/dl) or taking calcium supplements or history of recurrent kidney stones, Hyperparathyroidism ( >65pg/ml) and deranged serum electrolytes. 5.Use of concomitant medications that alter vitamin D metabolism (e.g phenytoin, corticosteroids) or absorption (e.g cholestyramine) or those that interfere with study endpoints. 6.History of cigarette smoking (more than 10 packs a year). 7.Deranged LFT (Liver enzymes >3 times upper limit of normal) or KFT (serum creatinine >1.2mg/dl) 8.Pregnant and nursing mothers

Design outcomes

Primary

MeasureTime frame
1)Asthma control test scores (ACT). 2)Frequency of asthma exacerbation. Timepoint: 0, 6weeks, 12weeks, 18weeks, 20weeks—

Secondary

MeasureTime frame
1)Predictive percentage of forced expiratory volume in 1st second (FeV1), FEV1/FVC. 2)Serum eosinophils levels. 3)Quality of life (AQLQ- Asthma quality of life questionnaire). 4)Percentage of patients requiring change in asthma treatment (step up / step down). 5)No. of emergency visits and hospitalizations for asthma. 6)Adverse events. Timepoint: 0, 6weeks, 12weeks, 18weeks, 20weeks—

Countries

India

Contacts

Public ContactPuneet

Maulana azad medical college

puneetgoel96@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026